OBJECTIVE: We sought to compare baseline and longitudinal plasma HIV-1 loads between herpes simplex virus type 2 (HSV-2)-seropositive and -seronegative individuals who are enrolled in a primary HIV-1 infection cohort in San Diego, California. DESIGN: The study was a retrospective cohort analysis. METHODS: We categorized antiretroviral-naive subjects on the basis of HSV-2 serostatus at baseline using an HSV-2 enzyme immunoassay. Low positive results (1.1-3.5) were confirmed by Western blotting. We compared baseline HIV-1 loads of the 2 groups using a linear model. To detect differences in HIV-1 dynamics, we analyzed longitudinal viral loads using a flexible semiparametric model, controlling for the time to antiretroviral therapy and stratifying by HIV-1 infection stage at entry. RESULTS: We studied 294 adult men. Ninety percent reported sex with men as their main HIV-1 risk factor. The seroprevalence of HSV-2 was 41.5%. The HSV-2-seropositive and -seronegative groups had similar baseline HIV-1 loads during acute infection (5.52 vs. 5.72 log(10) copies/mL; P=.39) and early infection (4.57 vs. 4.67 log(10) copies/mL; P=.5). Longitudinally, the difference in HIV-1 loads between HSV-2-seropositive and -seronegative men remained close to 0 during the first year of infection. CONCLUSIONS: HSV-2 serostatus has minimal influence on the dynamics of HIV-1 during acute and early HIV-1 infection.
OBJECTIVE: We sought to compare baseline and longitudinal plasma HIV-1 loads between herpes simplex virus type 2 (HSV-2)-seropositive and -seronegative individuals who are enrolled in a primary HIV-1 infection cohort in San Diego, California. DESIGN: The study was a retrospective cohort analysis. METHODS: We categorized antiretroviral-naive subjects on the basis of HSV-2 serostatus at baseline using an HSV-2 enzyme immunoassay. Low positive results (1.1-3.5) were confirmed by Western blotting. We compared baseline HIV-1 loads of the 2 groups using a linear model. To detect differences in HIV-1 dynamics, we analyzed longitudinal viral loads using a flexible semiparametric model, controlling for the time to antiretroviral therapy and stratifying by HIV-1 infection stage at entry. RESULTS: We studied 294 adult men. Ninety percent reported sex with men as their main HIV-1 risk factor. The seroprevalence of HSV-2 was 41.5%. The HSV-2-seropositive and -seronegative groups had similar baseline HIV-1 loads during acute infection (5.52 vs. 5.72 log(10) copies/mL; P=.39) and early infection (4.57 vs. 4.67 log(10) copies/mL; P=.5). Longitudinally, the difference in HIV-1 loads between HSV-2-seropositive and -seronegative men remained close to 0 during the first year of infection. CONCLUSIONS:HSV-2 serostatus has minimal influence on the dynamics of HIV-1 during acute and early HIV-1 infection.
Authors: H Nina Kim; Jing Wang; James Hughes; Robert Coombs; Jorge Sanchez; Stewart Reid; Sinead Delany-Moretlwe; Frances Cowan; Jonathan Fuchs; Susan H Eshleman; Leila Khaki; Moira A McMahon; Robert F Siliciano; Anna Wald; Connie Celum Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Brooke E Hoots; Michael G Hudgens; Stephen R Cole; Caroline C King; Robert S Klein; Kenneth H Mayer; Anne M Rompalo; Jack D Sobel; Denise J Jamieson; Jennifer S Smith Journal: Am J Epidemiol Date: 2011-03-03 Impact factor: 4.897
Authors: David M Butler; Davey M Smith; Edward R Cachay; George K Hightower; Charles Thomas Nugent; Douglas D Richman; Susan J Little Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Edward R Cachay; Simon D W Frost; Art F Y Poon; David Looney; Sherry M Rostami; Mary E Pacold; Douglas D Richman; Susan J Little; Davey M Smith Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Julie E Horbul; Stephen C Schmechel; Barrie R L Miller; Stephen A Rice; Peter J Southern Journal: PLoS One Date: 2011-07-27 Impact factor: 3.240
Authors: Jason D Barbour; Mariana M Sauer; Elizabeth R Sharp; Keith E Garrison; Brian R Long; Helena Tomiyama; Katia C Bassichetto; Solange M Oliveira; Maria C Abbate; Douglas F Nixon; Esper G Kallas Journal: PLoS One Date: 2007-10-24 Impact factor: 3.240